Flaxseed Lignans (Linum usitatissimum)

Nothing on your plate compares to flaxseed for lignans. Gram for gram, Linum usitatissimum is by far the richest dietary source of these plant compounds, which are classed as phytoestrogens. Flaxseed lignans are one of the four ingredients in EQUILI, our daily menopause-support formula — and the one with the closest connection to the idea our whole brand is named after, because they do not work until your gut bacteria act on them.

This page reviews what the research does and does not show. Some of it is genuinely encouraging. Some of it is not, and we would rather say so.

From seed to phytoestrogen

The principal lignan in flaxseed is SDG (secoisolariciresinol diglucoside). On its own, SDG is largely inert. The interesting chemistry happens in the gut: resident bacteria convert SDG first to secoisolariciresinol, then to enterodiol and enterolactone — the so-called “mammalian lignans.” These enterolignans resemble the body’s own estrogen closely enough to interact weakly with estrogen receptors, which is why lignans are described as phytoestrogens, and why they attract interest around menopause.

One point of precision worth making, because it is often got wrong: the frequently repeated claim that lignans act preferentially on the beta-type estrogen receptor comes from research on soy genistein, not on enterolignans. The most direct receptor study of enterolactone found it activates estrogen-mediated transcription with a preference for the alpha receptor. Enterolignans are best described as weak, selective estrogen-receptor agonists — not as a well-characterized ER-beta story.

Why the microbiome is not a marketing flourish here

The dependence on gut bacteria is not a soft claim. In germ-free rats — animals with no gut microbiome at all — fed the same lignan-containing diet, the gut contents held the intermediate compound but no enterodiol and no enterolactone whatsoever, and their urine was devoid of lignans entirely. Colonizing those animals with just four bacterial species restored the full conversion. Without the right bacteria, flaxseed lignans simply do not become active.

In humans, this shows up as substantial person-to-person variation. Enterolactone levels differ widely between individuals eating similar diets, and one large Finnish study of 2,753 adults found that people who had taken oral antibiotics had significantly lower blood enterolactone — an effect still detectable 12 to 16 months after treatment, with a dose-response by number of courses.

So the honest framing is that individual response to lignans genuinely varies, and gut bacteria are a major reason why. That is a real finding, not a slogan.

The one thing the science is sure about

If you consume flaxseed lignans, your body makes and absorbs enterolactone. This is beyond dispute and has been demonstrated with both whole seed and isolated extracts: 20 g of ground linseed daily roughly doubled to tripled serum enterolignans over two months, while an isolated lignan extract raised plasma enterolactone around nine-fold over a year. Enterolactone is used in research precisely because it is a reliable, objective marker that someone actually absorbed the lignans.

Absorption, in other words, is not the question. Whether it produces a clinical benefit is.

Hot flashes: what the trials actually found

Here is where honesty matters most, and where a distinction becomes critical. Most flaxseed menopause research used 25–40 g of whole ground flaxseed — a food-sized portion. A lignan extract is a different intervention. With that in mind:

• The largest and most rigorous trial, a phase III, double-blind, placebo-controlled study in 188 women, gave a flaxseed bar providing 410 mg of lignans daily for six weeks. Hot flash scores fell in both groups, with no significant difference from placebo. The authors concluded plainly that the results do not support flaxseed lignans for reducing hot flashes.
• A 2006 double-blind randomized trial in 99 postmenopausal women used 25 g of flaxseed (about 50 mg lignans) in muffins for 16 weeks and found no significant effect on menopause-specific quality of life or hot flashes.
• A 2010 double-blind trial using bread providing 46 mg of lignans daily — the dose closest to ours — found reductions in hot flashes and Kupperman index that were no greater than placebo.
• A 2012 trial is the only one to include a true lignan extract arm. Symptom scores improved within both the extract and whole-meal groups compared with their own starting points — but when the groups were properly compared against each other and placebo, the difference was not significant. Improvement measured against your own baseline is exactly what a placebo response looks like.
• A 2024 study in 145 perimenopausal women taking 10 g of flaxseed powder for three months did report substantial reductions across three menopause questionnaires, alongside confirmed rises in enterodiol and enterolactone. It is the most positive result available — but it was single-blind, its outcomes were entirely self-reported, and its placebo group improved by under 8%, which is far below the placebo response typically seen in this field.

Pooled analyses agree. A 2013 systematic review of flaxseed interventions concluded that flaxseed “is currently not indicated for the alleviation of vasomotor symptoms.” A 2016 meta-analysis found effects on hot flash severity and frequency that did not reach statistical significance. And the Cochrane review of phytoestrogens for menopausal symptoms found no conclusive evidence overall, noting that the one signal worth pursuing came from soy genistein concentrates rather than lignans.

The fair conclusion: the metabolism is real and measurable. The symptom benefit is not established. The better-blinded a flaxseed trial is, the more likely it is to be neutral.

Other outcomes studied

Bone. A 12-month randomized trial in 199 menopausal women taking 40 g of flaxseed daily found no significant difference in bone mineral density versus placebo, and a separate trial found no effect on bone formation or resorption markers. There is no positive human bone finding for flaxseed or its lignans.

Heart and metabolic markers. In carefully controlled trials in healthy postmenopausal women, an isolated flaxseed lignan complex providing 500 mg/day of SDG — nearly seven times our daily dose — did not improve endothelial function, and did not significantly change plasma lipids or antioxidant capacity, despite clearly raising enterolactone. A broader meta-analysis of blood lipids did find modest cholesterol reductions in the lignan-supplement subgroup, so the picture is not uniformly negative. But for blood pressure, a meta-analysis that separated preparations found the effect came from whole flaxseed and oil, with the lignan-extract subgroup showing no effect.

Breast tissue. Observational research in postmenopausal women has generally been reassuring, with higher lignan intake and higher enterolactone associated with lower breast cancer risk and better outcomes in several analyses. Interventional data are thinner: a promising uncontrolled pilot using 50 mg/day of SDG was followed by a 12-month randomized placebo-controlled trial in 180 women, whose primary endpoint was not met — the tissue-proliferation difference did not survive randomization. That trial’s most useful contribution is safety: over a full year at 50 mg/day of SDG, adverse events matched placebo, with the authors reporting no evidence of harm.

Safety and who should take care

Most of the cautions attached to flaxseed belong to the whole seed rather than a lignan extract: the bloating, flatulence and diarrhea that limited tolerability in trials came from the seed’s fiber content, and the need for generous fluid intake, the risk of delayed absorption of other medicines, and the cyanogenic glycosides naturally present in linseed are all whole-seed considerations that a small purified extract does not carry in the same way.

What does carry across is the estrogen-like activity itself, since that comes from the enterolignans. European regulators note that long-term use of linseed may have an estrogenic effect and advise against it in hormone-dependent tumors. Trials have not found stimulation of the womb lining or vaginal tissue, but the underlying data are limited, and observational findings in premenopausal women are less consistent than those in postmenopausal women. Anyone with a personal or family history of a hormone-sensitive cancer, and anyone taking tamoxifen, hormone therapy or blood-thinning medication, should speak to their doctor before taking a lignan supplement. Flaxseed lignans are not recommended during pregnancy or breastfeeding.

A note on health claims

Flaxseed lignans are sold in the EU as a food supplement, not a licensed medicine. There is no authorized EU health claim for flaxseed, linseed or lignans — for menopause or for anything else. A menopause-related claim for Linum usitatissimum was submitted and remains “on hold” pending a European Commission decision, meaning EFSA has never assessed it favorably.

One clarification, since it causes genuine confusion: there is an authorized EU claim that alpha-linolenic acid contributes to maintaining normal blood cholesterol. That claim belongs to ALA, the omega-3 fatty acid in flaxseed oil, requires a daily intake of 2 g of ALA, and has nothing to do with a lignan extract, which contains essentially none. We do not make that claim and it would not be legitimate for this product.

The research summarized here is shared for general information — to explain why these compounds are studied — not as a promise of results.

Flaxseed lignans are a food supplement ingredient, not a medicine, and individual responses vary.

Flaxseed lignans in EQUILI

Each daily dose of EQUILI (2 capsules) delivers 75 mg of flaxseed lignan extract, alongside red clover, sage and horsetail. A standardized extract gives a consistent daily amount without grinding seeds every morning — and because lignans are activated by your gut bacteria, they sit at the center of the microbiome science this brand is built on. Whether that translates into symptom relief for any individual remains, on the evidence above, genuinely uncertain.

References

• Linus Pauling Institute, Micronutrient Information Center. Lignans. lpi.oregonstate.edu
• Woting A, Clavel T, Loh G, Blaut M. Bacterial transformation of dietary lignans in gnotobiotic rats. FEMS Microbiol Ecol. 2010. PubMed 20370826
• Kilkkinen A, et al. Use of oral antimicrobials decreases serum enterolactone concentration. Am J Epidemiol. 2002. PubMed 11867359
• Penttinen P, et al. Diet-derived polyphenol metabolite enterolactone is a tissue-specific estrogen receptor activator. Endocrinology. 2007. PubMed 17628008
• Pruthi S, et al. A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: NCCTG N08C7. Menopause. 2012. PubMed 21900849
• Lewis JE, et al. A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause. Menopause. 2006. PubMed 16837885
• Simbalista RL, et al. Consumption of a flaxseed-rich food is not more effective than a placebo in alleviating the climacteric symptoms of postmenopausal women. J Nutr. 2010. PubMed 20007337
• Colli MC, et al. Evaluation of the efficacy of flaxseed meal and flaxseed extract in reducing menopausal symptoms. J Med Food. 2012. PubMed 22925074
• Shrivastava R, et al. Effects of flaxseed on perimenopausal symptoms: findings from a single-blind, randomized, placebo-controlled study. Cureus. 2024. PMC11448742
• Dew TP, Williamson G. Controlled flax interventions for the improvement of menopausal symptoms and postmenopausal bone health: a systematic review. Menopause. 2013. PubMed 23571524
• Ghazanfarpour M, et al. Effects of flaxseed and Hypericum perforatum on hot flush, vaginal atrophy and estrogen-dependent cancers in menopausal women: a systematic review and meta-analysis. Avicenna J Phytomed. 2016. PMC4930534
• Lethaby A, et al. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database of Systematic Reviews. 2013. PubMed 24323914
• Dodin S, et al. The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women. J Clin Endocrinol Metab. 2005. PubMed 15613422
• Lucas EA, et al. Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. J Clin Endocrinol Metab. 2002. PubMed 11932276
• Hallund J, et al. A lignan complex isolated from flaxseed does not affect plasma lipid concentrations or antioxidant capacity in healthy postmenopausal women. J Nutr. 2006. PubMed 16365068
• Hallund J, et al. Daily consumption for six weeks of a lignan complex isolated from flaxseed does not affect endothelial function in healthy postmenopausal women. J Nutr. 2006. PubMed 16920847
• Pan A, et al. Meta-analysis of the effects of flaxseed interventions on blood lipids. Am J Clin Nutr. 2009. PMC3361740
• Ursoniu S, et al. Effects of flaxseed supplements on blood pressure: a systematic review and meta-analysis of controlled clinical trials. Clin Nutr. 2016. PubMed 26071633
• Buck K, et al. Meta-analyses of lignans and enterolignans in relation to breast cancer risk. Am J Clin Nutr. 2010. PubMed 20463043
• Fabian CJ, et al. Randomized phase IIB trial of the lignan secoisolariciresinol diglucoside in premenopausal women at increased risk for breast cancer. Cancer Prev Res. 2020. PMC7335358
• European Medicines Agency, HMPC. European Union herbal monograph on Linum usitatissimum L., semen. ema.europa.eu
• Commission Regulation (EU) No 432/2012 establishing a list of permitted health claims. eur-lex.europa.eu

This page is for general information and is not a substitute for medical advice. Food supplements should not be used as a substitute for a varied, balanced diet and a healthy lifestyle.